124 related articles for article (PubMed ID: 19951884)
1. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
Kato H; Taji H; Ogura M; Kagami Y; Oki Y; Tsujimura A; Fuwa N; Kodaira T; Seto M; Yamamoto K; Morishima Y
Clin Lymphoma Myeloma; 2009 Dec; 9(6):443-8. PubMed ID: 19951884
[TBL] [Abstract][Full Text] [Related]
2. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
[TBL] [Abstract][Full Text] [Related]
3. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.
Arcaini L; Morello L; Tucci A; Rusconi C; Ladetto M; Rattotti S; Bonfichi M; Bottelli C; Gabutti C; Bernasconi P; Varettoni M; Gotti M; Troletti D; Guerrera ML; Fiaccadori V; Sciarra R; Ferretti VV; Alessandrino EP; Rossi G; Morra E
Am J Hematol; 2015 Mar; 90(3):230-4. PubMed ID: 25502635
[TBL] [Abstract][Full Text] [Related]
7. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
8. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
9. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
10. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation.
Demirer T; Ayli M; Fen T; Ozcan M; Arat M; Buyukberber S; Arslan O; Gurman G; Akan H; Ilhan O
Bone Marrow Transplant; 2004 Nov; 34(9):781-6. PubMed ID: 15354206
[TBL] [Abstract][Full Text] [Related]
11. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
12. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
13. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
14. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
17. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
18. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma.
Han LN; Zhou J; Hirose T; Imai Y; Ishiguro T; Chou T
Int J Hematol; 2006 Aug; 84(2):174-81. PubMed ID: 16926142
[TBL] [Abstract][Full Text] [Related]
20. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
